プロモーションスケジュール MiNK Therapeutics, Inc.
詳細なスケジュール
簡易グラフ
会社について
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
| IPO date |
2021-10-15 |
| ISIN |
US6036931029 |
| Industry |
Biotechnology |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://minktherapeutics.com
|
| Цена ао |
0.938 |
| 1日あたりの価格変動: |
+8.92% (0.5279) |
| 週ごとの価格変動: |
+9.73% (0.524) |
| 月ごとの料金変更: |
-20.15% (0.7201) |
| 3ヶ月間の価格変動: |
-23.57% (0.7523) |
| 半年間の価格変動: |
-35.39% (0.89) |
| 年間の価格変動: |
-46.26% (1.07) |
| 3年間の価格推移: |
-87.05% (4.44) |
| 5年間の価格推移: |
0% (0.575) |
| 10年間の価格推移: |
0% (0.575) |
| 年初からの価格変動: |
-15.76% (0.6826) |
|
|
過小評価
| 名前 |
意味 |
学年 |
| P/S |
0.0222 |
10 |
| P/BV |
-1.94 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
-1.4 |
0 |
| 合計: |
|
5 |
|
効率
| 名前 |
意味 |
学年 |
| ROA, % |
-493.33 |
0 |
| ROE, % |
124.38 |
10 |
| 合計: |
|
3.33 |
|
|
|
配当金
| 名前 |
意味 |
学年 |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| 合計: |
|
0 |
|
義務
| 名前 |
意味 |
学年 |
| Debt/EBITDA |
0 |
10 |
| 合計: |
|
10 |
|
成長の衝動
| 名前 |
意味 |
学年 |
| 収益性 Revenue, % |
391891.74 |
10 |
| 収益性 Ebitda, % |
0.2398 |
1 |
| 収益性 EPS, % |
-35.29 |
0 |
| 合計: |
|
2.4 |
|
| スーパーバイザー |
役職 |
支払い |
生年 |
| Dr. Garo H. Armen Ph.D. |
Executive Chairman |
N/A |
1953 (72 年) |
| Dr. Jennifer S. Buell Ph.D. |
President, CEO & Director |
916.75k |
1975 (50 年) |
| Dr. Marcus Antonius van Dijk Ph.D. |
Chief Scientific Officer |
458.28k |
1962 (63 年) |
| Ms. Christine M. Klaskin |
Treasurer |
29.62k |
1966 (59 年) |
| Joy Zhou Ph.D. |
Vice President & Head of CMC |
N/A |
|
| Mr. Robert Foster |
Director Of Legal & Business Affairs |
|
|
